Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Why I Chose to Be Part of RheumPAC

Padmapriya Sivaraman, MD  |  Issue: January 2019  |  January 4, 2019

During one advocacy visit to Congress, I had the chance to meet Rep. Pete Sessions (R-TX 32nd District [until Jan. 3, 2019]), who has always been a champion for healthcare reforms. Rep. Sessions made time in his busy schedule to spend with our group. The various topics discussed included putting patient care first by changing the policy of step therapy, also known as fail first, which forces rheumatologists to use therapies preferred by insurance companies rather than conventional wisdom and medical judgment, thereby delaying medical care and putting patient health at unnecessary risk. The need to streamline the prior authorization process was also discussed.

Millions of Americans, including children, suffer from arthritis and do not have access to specialist care due to rheumatology workforce shortages. Thus, we discussed how Congress can support policies to help expand the rheumatology workforce and manage this need. Increasing financial support for rheumatology fellowships and an expedited process for foreign physicians to work in the U.S. under the H-1B visa program would help tackle this shortage.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reimbursement is on the decline, and this has affected our practice. We discussed ways Congress can help, such as with public service loan forgiveness. This is one viable option to help new rheumatologists pay off loans or reduce total loan payments.

The lack of adequate investment in medical research is also a concern. The good news: Collaborative efforts of the various rheumatology committees and Congress led to the approval of millions of dollars in research funding for arthritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During our entire interaction, Rep. Sessions showed a keen interest in being our liaison, taking our message to Congress and educating members on the various issues affecting rheumatologists and the barriers we must overcome to provide quality service to our patient population. It is very important that we build more bridges in places that matter the most, such as Congress, to establish a healthcare policy that works for both rheumatology professionals and patients.
I would strongly recommend every rheumatologist associate themselves with RheumPAC by volunteering and providing generous donations. For more information about RheumPAC, click here.

Disclaimer: Contributions to RheumPAC are used for political purposes and are not tax deductible. They must be voluntary and made with personal funds. Federal law prohibits contributions to RheumPAC from corporations, but ask us about the RheumPAC Advocacy Fund, which does support advocacy with soft dollars. Contributions to RheumPAC can only be made by U.S, citizens or permanent resident aliens.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & AdvocacyOpinionRheuminationsSpeak Out Rheum Tagged with:health advocacyPadmapriya SivaramanRheumatology Political Action CommitteeRheumPAC

Related Articles

    Advancing the ACR’s Legislative Priorities in 2021

    January 11, 2021

    With a new Congress and many new legislators in key leadership positions, your support today will help RheumPAC start the year off strong.

    I RheumPAC, Do You?

    September 1, 2009

    For many years, the ACR board of directors and Government Affairs Committee have done exemplary work in keeping members abreast of legislative regulatory issues that affect all aspects of rheumatology, including patient and physician/healthcare professional issues, education, and research. Through advocacy, the ACR advances rheumatology and fosters excellence in the care of people with, or at risk for, arthritis and rheumatic and musculoskeletal diseases. One might say that advocacy is a cornerstone of this organization.

    A Huge Thank You to 251 People

    March 18, 2011

    RheumPAC supporters are helping to advance rheumatology

    November, a Busy Month for RheumPAC

    October 21, 2022

    In November, RheumPAC will be leading its annual matching campaign and hosting two events at ACR Convergence 2022. Thanks to matching donors, every contribution in November will be amplified.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences